期刊文献+

非IgM型淋巴浆细胞淋巴瘤临床及生物学特征研究 被引量:6

Clinical and biological characteristics of non-IgM lymphoplasmacytic iymphoma
原文传递
导出
摘要 目的 探索非IgM型淋巴浆细胞淋巴瘤(LPL)患者的临床及生物学特征,并与华氏巨球蛋白血症(WM)进行比较,探索两者的异同.方法 对2000年1月至2013年12月收治的13例非IgM型LPL患者临床资料进行回顾性分析,应用荧光原位杂交技术(FISH)对其中7例患者标本进行检查.结果 13例患者中,男7例,女6例,中位发病年龄63 (43~74)岁.2例分泌单克隆IgA,6例分泌单克隆IgG,5例不分泌单克隆性免疫球蛋白.以贫血为主要表现者7例,以皮肤黏膜出血和浅表淋巴结肿大为主要表现者各2例,出现B症状(发热、盗汗、体重减轻)者8例.所有患者均骨髓受累并表现贫血,10例患者为血常规2系或以上减少.行流式细胞术检查的5例患者中CD19、CD20、CD22和CD25均阳性,CD10、CD38和CD103均阴性,CD5弱阳性1例(该患者CD23阴性),slgM阳性1例,CD23和CDllc阳性各2例,FMC7阳性3例.7例患者行细胞遗传学检查,未见异常核型,应用FISH检查发现其中2例患者伴有6q缺失.结论 结合文献报道,非IgM型LPL与WM患者临床及生物学特征相似. Objective To observe the clinical and biological characteristics of Non-IgM-secreting lymphoplasmacytic lymphoma (LPL) and draw the differences between non-IgM LPL and Waldenstr(o)m macroglobulinemia (WM).Methods Records of 13 patients with non-IgM LPL were retrospectively analyzed between January 2000 and December 2013.The cytogenetic aberrations were detected by fluorescence in situ hybridisation (FISH).Results In the cohort,7 males and 6 females with a median age of 63 years (range 43 to 74),two patients were IgA secreting,6 with IgG secreting and 5 patients without monoclonal globulin.The major complaint at diagnosis included anemia associated symptom (53.8%),mucocutaneous hemorrhage and superficial lymphadenopathy (15.4%).Eight patients had B symptom at diagnosis.All of the 13 patients had bone marrow involvement and anemia,and 10 patients had 2 or 3 lineage cytopenia.In 5 patients with available immunophenotypic data,all expressed CD19,CD20,CD22 and CD25,but missed the expression of CD10,CD103 and CD38.Two cases had CD5 or sIgM positive alone.Another 2 patients were CD23 or CDllc positive and 3 patients were FMC7 positive.Cytogenetic aberrations had been detected by FISH in 7 patients,but only two (28.6%) patients had aberrations with del (6q).Conclusions The clinical and biological characteristics had no significantly difference between non-IgM LPL and WM.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第6期493-496,共4页 Chinese Journal of Hematology
基金 国家科技支撑计划(2014BAI09B12) 国家自然科学基金(81200395、81370632) 卫生公益性行业科研专项(201202017)
关键词 淋巴瘤 非免疫球蛋白M 临床特征 免疫表型分型 细胞遗传学 Lymphoma non-Immunoglobulin M Clinical characteristics Immunophenotyping Cytogenetics
  • 相关文献

参考文献3

二级参考文献49

  • 1姚建新,李建勇.126例慢性淋巴细胞白血病免疫表型分析[J].中国血液流变学杂志,2006,16(3):367-369. 被引量:6
  • 2Swerdlow SH, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [M]. Lyon: IARC, 2008.
  • 3Cro L, Guffanti A, Colombi prognostic significance of a M, et al. Diagnostic role and simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias [J]. Leukemia, 2003, 17( 1 ): 125-132.
  • 4Tworek JA, Singleton TP, Schnitzer B, et al. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma [J]. Am J Clin Pathol, 1998, 110 (5): 582-589.
  • 5Matutes E, Owusu-Ankomah K, Morilla R, et al. The immuno- logical profile of B-cell disorders and proposal of a scoring sys- tem for the diagnosis of CLL[J]. Leukemia, 1994, 8(10): 1640- 1645.
  • 6Kraus TS, Sillings CN, Saxe DF, et al. The role of CDllc ex- pression in the diagnosis of mantle cell lymphoma [J]. Am J Clin Pathol, 2010, 134(2): 271-277.
  • 7Gao J, Peterson L, Nelson B, et al. Immunophenotypic varia- tions in mantle cell lymphoma[J]. Am J Clin Pathol, 2009, 132 (5): 699-706.
  • 8Medd PG, Clark N, Leyden K, et al. A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t (11;14) translocation of mantle cell lymphoma [J]. Cytometry B Clin Cytom, 2011, 80 (4): 230-237.
  • 9Jevremovic D, Dronca RS, Morice WG, et al. CD5 + B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma [J]. Leuk Res, 2010, 34 (9): 1235-1238.
  • 10Dronca RS, Jevremovic D, Hanson CA, et al. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity [J]. Cytometry B Clin Cytom, 2010, 78 Suppl 1: S35-41.

共引文献24

同被引文献35

  • 1侯宁,张彤,莫伏根.CD30阳性的大B细胞淋巴瘤临床病理分析[J].临床与实验病理学杂志,2005,21(6):655-658. 被引量:2
  • 2张金萍,陈超,杨毅.Toll样受体2和4在新生儿感染时的变化及其临床意义[J].中华儿科杂志,2007,45(2):130-133. 被引量:15
  • 3Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
  • 4Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
  • 5Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
  • 6Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia[J]. Blood, 2009, 113 ( 18 ): 4163-4170.
  • 7Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom' s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) [J]. Leuk Res, 2010, 34 ( 10): 1340-1343.
  • 8Kastritis E, Zervas K, Repoussis P, et al. Prognostication inyoung and old patients with Waldenstr6m's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase [J]. Clin Lymphoma Myeloma, 2009, 9( 1 ): 50-52.
  • 9Treon SP. How I treat Waldenstr6m macroglobulinemia [J]. Blood, 2009, 114(12): 2375-2385.
  • 10Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreat- ed Waldenstr6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma [J]. J Clin Oncol, 2013, 31 (3): 301-307.

引证文献6

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部